DrugPatentWatch Database Preview
e - Profile
Company Disclosures: US Patents for e
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Number | Approval Date | Patent No. | Assignee | Estimated Patent Expiration | Status | Orphan | Source |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Immunex | ENBREL | etanercept | VIAL; SUBCUTANEOUS | 103795 | 001 | 1998-11-02 | Start Trial | Immunex Corporation (Seattle, WA) | 2012-03-07 | RX | Orphan | company |
Immunex | ENBREL | etanercept | VIAL; SUBCUTANEOUS | 103795 | 001 | 1998-11-02 | Start Trial | Immunex Corporation (Seattle, WA) | 2014-02-25 | RX | Orphan | company |
Immunex | ENBREL | etanercept | VIAL; SUBCUTANEOUS | 103795 | 001 | 1998-11-02 | Start Trial | Immunex Corporation (Seattle, WA) | 2009-09-05 | RX | Orphan | company |
Immunex | ENBREL | etanercept | VIAL; SUBCUTANEOUS | 103795 | 001 | 1998-11-02 | Start Trial | Immunex Corporation (Seattle, WA) | 2009-09-11 | RX | Orphan | company |
Immunex | ENBREL | etanercept | VIAL; SUBCUTANEOUS | 103795 | 001 | 1998-11-02 | Start Trial | 2009-09-05 | RX | Orphan | company | |
Immunex | ENBREL | etanercept | VIAL; SUBCUTANEOUS | 103795 | 001 | 1998-11-02 | Start Trial | Immunex Corporation (Seattle, WA) | 2009-09-05 | RX | Orphan | company |
Immunex | ENBREL | etanercept | VIAL; SUBCUTANEOUS | 103795 | 001 | 1998-11-02 | Start Trial | Immunex Corporation (Thousand Oaks, CA) | 2019-04-19 | RX | Orphan | company |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Number | >Approval Date | >Patent No. | >Assignee | >Estimated Patent Expiration | >Status | >Orphan | >Source |
Patent Text Search: US Patents for e
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Number | Approval Date | Patent No. | Assignee | Estimated Patent Expiration | Status | Orphan | Source |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Shire | ELAPRASE | idursulfase | INJECTABLE; IV (INFUSION) | 125151 | 001 | 2006-07-24 | Start Trial | SIO2 MEDICAL PRODUCTS, INC. (Auburn, AL) | 2033-03-11 | RX | Orphan | search |
Shire | ELAPRASE | idursulfase | INJECTABLE; IV (INFUSION) | 125151 | 001 | 2006-07-24 | Start Trial | ForSight Vision4, Inc. (Menlo Park, CA) | 2029-01-29 | RX | Orphan | search |
Shire | ELAPRASE | idursulfase | INJECTABLE; IV (INFUSION) | 125151 | 001 | 2006-07-24 | Start Trial | Forsight Vision4, Inc. (Menlo Park, CA) | 2029-01-29 | RX | Orphan | search |
Shire | ELAPRASE | idursulfase | INJECTABLE; IV (INFUSION) | 125151 | 001 | 2006-07-24 | Start Trial | Shire Human Genetic Therapies, Inc. (Lexington, MA) | 2031-06-08 | RX | Orphan | search |
Shire | ELAPRASE | idursulfase | INJECTABLE; IV (INFUSION) | 125151 | 001 | 2006-07-24 | Start Trial | SIO2 MEDICAL PRODUCTS, INC. (Auburn, AL) | 2033-03-11 | RX | Orphan | search |
Shire | ELAPRASE | idursulfase | INJECTABLE; IV (INFUSION) | 125151 | 001 | 2006-07-24 | Start Trial | Shire Human Genetic Therapies, Inc. (Lexington, MA) | 2031-06-08 | RX | Orphan | search |
Shire | ELAPRASE | idursulfase | INJECTABLE; IV (INFUSION) | 125151 | 001 | 2006-07-24 | Start Trial | SIO2 MEDICAL PRODUCTS, INC. (Auburn, AL) | 2029-05-13 | RX | Orphan | search |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Number | >Approval Date | >Patent No. | >Assignee | >Estimated Patent Expiration | >Status | >Orphan | >Source |